Favourable treatment of pyoderma gangrenosum with visilizumab in severe ulcerative colitis case

Background: Pyoderma gangrenosum (PG) is a misleading designation for an idiopathic ulcerating cutaneous disease. More than 50% of patients do not have an associated disease. The incidence of PG in ulcerative colitis is low (1–5%), however 36–50% of all the patients have IBD. The activity of PG may or may not follow the activity of the bowel disease. Visilizumab (Nuvion, PDL Bio Pharma, USA) is a humanized IgG2 monoclonal antibody that binds to the human CD3 epsilon chain expressed on human T cells. Visilizumab induces rapid production of selective chemokines including CXCL-10 (IP-10) and reduces CXCR3-mediated…